Sign in
Taking peoplePhase 2

A Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablet in the Treatment of Postherpetic Neuralgia

Key facts

Who runs it
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
200 people, planned
Started
Aug 2026
Expected to end
Jun 2027
Type of study
Interventional, 5 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • HL-1186
  • HL-1186 placebo
  • Pregabalin capsule
  • Pregabalin capsule placebo
Record updated
11 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Aged ≥ 18 years, of either sex
  • Pain persists for 1 month or more after healing of skin lesions in patients with herpes zoster
  • Participants fully understand the purpose, characteristics, methods of the trial and possible AEs, voluntarily participate in the trial and sign the ICF, or have their legal guardian sign the ICF on their behalf

Who cannot take part

  • Participants who have used drugs that may damage nerves (such as tumor chemotherapy drugs) after being diagnosed with PHN
  • The baseline NRS collection begins within the 5 half-lives following the last use of the prohibited drug
  • Participants who have previously used pregabalin with inadequate efficacy or intolerance
  • Participants who have undergone major surgery within 8 weeks prior to enrollment or plan to undergo any surgery during the trial period
  • Participants with any pain other than PHN, or with other diseases that the researcher considers to potentially affect the evaluation of PHN
  • Participants who may be allergic to the active ingredients or excipients of HL-1186 Tablet, HL-1186 Tablet placebo, pregabalin capsule or pregabalin capsule placebo, have an allergic constitution, or have a history of allergies to ≥ 3 substances
  • Clinically significant abnormalities in the 12-lead electrocardiogram (ECG) during the screening period, or complicated with severe cardiopulmonary diseases, which are deemed unsuitable for inclusion by the researcher
  • Participants with a history of malignant tumors within 2 years prior to screening
  • Participants with a history of alcoholism or drug abuse within 2 years before screening
  • Participants with positive human immunodeficiency virus antibody, positive syphilis serological test, positive hepatitis B virus surface antigen with hepatitis B virus DNA > ULN, or positive hepatitis C virus antibody with hepatitis C virus RNA > ULN
  • Female participants who are pregnant, breastfeeding (within 1 year after delivery), or with a positive pregnancy test
  • Participants deemed by the investigator to be unsuitable for participating in this trial for any reason

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial to evaluate the safety, efficacy and pharmacokinetic (PK) profile of HL-1186 Tablet in patients with postherpetic neuralgia (PHN).

The 5 groups in the trial

  • HL-1186 High DoseTreatment being tested

    Participants will receive continuous HL-1186 administration for 12 weeks

    Treatment: HL-1186 and Pregabalin capsule placebo

  • HL-1186 Medium DoseTreatment being tested

    Participants will receive continuous HL-1186 administration for 12 weeks

    Treatment: HL-1186, HL-1186 placebo, and Pregabalin capsule placebo

  • HL-1186 Low DoseTreatment being tested

    Participants will receive continuous HL-1186 administration for 12 weeks

    Treatment: HL-1186, HL-1186 placebo, and Pregabalin capsule placebo

  • PregabalinExisting treatment, for comparison

    Participants will receive continuous Pregabalin administration for 12 weeks

    Treatment: HL-1186 placebo and Pregabalin capsule

  • PlaceboPlacebo, for comparison

    Participants will receive continuous placebo administration for 12 weeks

    Treatment: HL-1186 placebo and Pregabalin capsule placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
11 August 2026